AstraZeneca Results Presentation Deck

Hypertension ~120m Chronic Kidney Disease ~35.5m Heart Failure ~6.5m Farxiga BioPharmaceuticals - R&D highlights Advancing potential novel medicines to address unmet needs across CKD and HF Farxiga Uncontrolled Hypertension ¹ CEO Opening Remarks ~37m baxdrostat ~7m baxdrostat/dapagliflozin ~20m balcinerone/ dapagliflozin ~12m² Financial Results Farxiga FDC lifecycle management monotherapy Oncology Resistant Hypertension¹ High proteinuria ~12m BioPharmaceuticals zibotentan/dapagliflozin ~4m³ Rare Disease 4 CEO Closing Remarks potential new medicines tailored approach to address biological mechanisms driving disease progression Phase III initiated zibo/dapa in CKD with high proteinuria Phase III initiation planned before YE, baxdrostat in HTN Broad disease epidemiology figures are based on US prevalent patients as per CDC. 1. Simone Romano et al. Internal and Emergency Medicine, 02 August 2023. Hypertension, uncontrolled hypertension and resistant hypertension: prevalence, comorbidities and prescribed medications in 228,406 adults resident in urban areas. 2. Jens van de Wouw et al. Front. Physiol., 04 September 2019 Sec. Clinical and Translational Physiology Volume 10-2019. 3. CKD in the General Population, NIDDK. 4. 24 CKD Prevalence by hypertension status and year, NHANES, ~25-30% of adults diagnosed with hypertension have CKD. 1 dapagliflozin = Farxiga; m = millions; CKD = chronic kidney disease; HF = heart failure; HTN = hypertension

View entire presentation